Inbar Levi

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Mical Paul, George L. Daikos, Emanuele Durante‐Mangoni et al. · The Lancet Infectious Diseases · 2018 · 624 citations

Life Sciences, Infectious Diseases, Microbiology +14

Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity

David Hagin, Tal Freund, Michal Navon et al. · Journal of Allergy and Clinical Immunology · 2021 · 189 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +15

Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial

Yaakov Dickstein, Jonathan Lellouche, Maayan Ben Dalak Amar et al. · Clinical Infectious Diseases · 2018 · 126 citations

Life Sciences, Infectious Diseases, Microbiology +17

Characterization of tumor infiltrating Natural Killer cell subset

Inbar Levi, Hagai Amsalem, Aviram Nissan et al. · Oncotarget · 2015 · 121 citations · Full text

Life Sciences, Immunology, Oncology +13

Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes

Amir Nutman, Jonathan Lellouche, Elizabeth Temkin et al. · Clinical Microbiology and Infection · 2020 · 78 citations

Life Sciences, Infectious Diseases, Pharmacology +16